Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients

Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2016-02, Vol.43 (C), p.43-48
Main Authors: Qiu, Yuan-wang, Huang, Li-hua, Yang, Wen-long, Wang, Zhen, Zhang, Bo, Li, Yi-guang, Su, Ting-ting, Zhou, Hong-yan, Xu, Wei, Wang, Xue-dong, Dai, Ya-ping, Gan, Jian-he
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - administration & dosage
Biomarkers - blood
China - epidemiology
Chronic hepatitis B
Entecavir
Female
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B e Antigens - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - epidemiology
Hepatitis B, Chronic - immunology
Humans
Infectious Disease
Male
Middle Aged
Pulmonary/Respiratory
Recurrence
Relapse
Seroconversion - drug effects
Treatment Outcome
Viral Load - immunology
Withdrawal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Hepatitis B surface antigen (HBsAg) levels at hepatitis B e antigen (HBeAg) seroconversion may be an effective predictor of virological relapse. • The variation in HBsAg levels can help guide the timing of cessation of entecavir treatment. • Off-treatment virological relapse rates after stopping entecavir treatment were assessed.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2015.10.019